Matches in SemOpenAlex for { <https://semopenalex.org/work/W11476077> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W11476077 endingPage "54" @default.
- W11476077 startingPage "1449" @default.
- W11476077 abstract "Disorders characterized by cutaneous hyperpigmentation (HP) are among the most common complaints in dermatologists' offices. These patients are also some of the most difficult to treat since current therapeutic regimens have high irritation rates and mediocre efficacy. Moreover, current regimens have the potential to induce post-inflammatory HP (PIH), a secondary disease that is more difficult to treat.To measure the effectiveness of a novel blend of primarily natural ingredients that inhibits all but one of the steps in melanin synthesis, activation and distribution. Three common types of HP were treated and compared with one of the most commonly prescribed available regimens. This comprises two prescription products and two nonprescription products containing known depigmenting lightening ingredients.The initial trial consisted of 56 females of 3 different races were treated in a 3-armed parallel, investigatorblinded prospective controlled clinical trial of 18 weeks duration. The treatment phase was 12 weeks long, followed by a 6 week, nontreatment regression phase. This trial was conducted in the winter at over 6,000 feet above sea level. The natural ingredient (NI) blend consists of two cosmeceutical products together containing 22 ingredients. A second 1-year open trial of 31 panelists of 3 races was instituted to document continual improvement using both NI products without irritation and sensitization.The novel herbal blend regimens had comparable efficacy in treating HP and preventing rebound of mottled HP, dyschromia and melasma as the commercial regimen containing two prescription products. The 12-month open study demonstrated continued visible improvement of the HP with NI regimens without irritation and sensitization.The novel primarily natural ingredient product regimens are equally effective in treating three types of cutaneous HP as is a regimen containing prescription hydroquinone 4%, tretinoin 0.05% and two nonprescription leave on products." @default.
- W11476077 created "2016-06-24" @default.
- W11476077 creator A5001298769 @default.
- W11476077 creator A5017261351 @default.
- W11476077 creator A5049063903 @default.
- W11476077 date "2013-12-01" @default.
- W11476077 modified "2023-09-27" @default.
- W11476077 title "Blockade of melanin synthesis, activation and distribution pathway by a nonprescription natural regimen is equally effective to a multiple prescription-based therapeutic regimen." @default.
- W11476077 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24301247" @default.
- W11476077 hasPublicationYear "2013" @default.
- W11476077 type Work @default.
- W11476077 sameAs 11476077 @default.
- W11476077 citedByCount "2" @default.
- W11476077 countsByYear W114760772015 @default.
- W11476077 countsByYear W114760772021 @default.
- W11476077 crossrefType "journal-article" @default.
- W11476077 hasAuthorship W11476077A5001298769 @default.
- W11476077 hasAuthorship W11476077A5017261351 @default.
- W11476077 hasAuthorship W11476077A5049063903 @default.
- W11476077 hasConcept C126322002 @default.
- W11476077 hasConcept C142724271 @default.
- W11476077 hasConcept C16005928 @default.
- W11476077 hasConcept C168563851 @default.
- W11476077 hasConcept C203014093 @default.
- W11476077 hasConcept C2426938 @default.
- W11476077 hasConcept C2776677263 @default.
- W11476077 hasConcept C2776728111 @default.
- W11476077 hasConcept C2777063393 @default.
- W11476077 hasConcept C2780532717 @default.
- W11476077 hasConcept C2781413609 @default.
- W11476077 hasConcept C45904493 @default.
- W11476077 hasConcept C535046627 @default.
- W11476077 hasConcept C71924100 @default.
- W11476077 hasConcept C98274493 @default.
- W11476077 hasConceptScore W11476077C126322002 @default.
- W11476077 hasConceptScore W11476077C142724271 @default.
- W11476077 hasConceptScore W11476077C16005928 @default.
- W11476077 hasConceptScore W11476077C168563851 @default.
- W11476077 hasConceptScore W11476077C203014093 @default.
- W11476077 hasConceptScore W11476077C2426938 @default.
- W11476077 hasConceptScore W11476077C2776677263 @default.
- W11476077 hasConceptScore W11476077C2776728111 @default.
- W11476077 hasConceptScore W11476077C2777063393 @default.
- W11476077 hasConceptScore W11476077C2780532717 @default.
- W11476077 hasConceptScore W11476077C2781413609 @default.
- W11476077 hasConceptScore W11476077C45904493 @default.
- W11476077 hasConceptScore W11476077C535046627 @default.
- W11476077 hasConceptScore W11476077C71924100 @default.
- W11476077 hasConceptScore W11476077C98274493 @default.
- W11476077 hasIssue "12" @default.
- W11476077 hasLocation W114760771 @default.
- W11476077 hasOpenAccess W11476077 @default.
- W11476077 hasPrimaryLocation W114760771 @default.
- W11476077 hasRelatedWork W1998825789 @default.
- W11476077 hasRelatedWork W2007582870 @default.
- W11476077 hasRelatedWork W2018486250 @default.
- W11476077 hasRelatedWork W2035196124 @default.
- W11476077 hasRelatedWork W2162913078 @default.
- W11476077 hasRelatedWork W2188229029 @default.
- W11476077 hasRelatedWork W2931257963 @default.
- W11476077 hasRelatedWork W3145374959 @default.
- W11476077 hasRelatedWork W3214446229 @default.
- W11476077 hasRelatedWork W3638058 @default.
- W11476077 hasVolume "12" @default.
- W11476077 isParatext "false" @default.
- W11476077 isRetracted "false" @default.
- W11476077 magId "11476077" @default.
- W11476077 workType "article" @default.